Cyran Clemens C, Sennino Barbara, Chaopathomkul Bundit, Fu Yanjun, Rogut Victor, Shames David M, Wendland Michael F, McDonald Donald M, Brasch Robert C
Center for Pharmaceutical and Molecular Imaging, Department of Radiology, University of California San Francisco, San Francisco, CA 94143-0628, USA.
Invest Radiol. 2008 May;43(5):298-305. doi: 10.1097/RLI.0b013e318164b71d.
To evaluate the potential of quantitative assays of vascular characteristics based on dynamic contrast-enhanced magnetic resonance imaging (MRI) using a macromolecular contrast medium (MMCM) to search for and measure effects of dimethyl sulfoxide (DMSO) on cancer vasculature with microscopic correlations.
Saline-treated control (n = 8) and DMSO-treated (n = 7) human breast cancer xenografts (MDA-MB-435) in rats were imaged dynamically by MMCM-enhanced MRI using albumin-(Gd-DTPA)27-(biotin)11 (molecular weight approximately 90 kDa), before and after a 1-week, 3-dose treatment course. After the posttreatment MRI examinations, tumors were perfused with lectin and fixative and subsequently stained with RECA-1 and streptavidin for quantitative fluorescent microscopy. Quantitative MRI estimates of cancer microvessel permeability (KPS; microL/min.100 cm3) and fractional plasma volume (fPV; %) were based on a 2-compartment kinetic model. Fluorescent microscopy yielded estimates of MMCM extravasation and vascular density that were compared to the MRI results.
DMSO decreased cancer vascular endothelial permeability significantly (P < 0.05) from tumor KPSday0 = 19.3 +/- 8.8 microL/min.100 cm3 to KPSday7 = 0 microL/min.100 cm3). K values in the saline-treated tumors did not change significantly. The amount of extravasated albumin-Gd-(DTPA)27-(biotin)11, as assayed by a fluorescently labeled streptavidin stain that strongly binds to the biotin tag on the MMCM, was significantly (P < 0.05) lower in the DMSO-treated cancers than in the control cancers (57.7% +/- 5.5% vs. 34.2% +/- 4.9%). Tumor vascular richness as reflected by the MRI-assayed fPV and by the RECA-1 and lectin-stained microscopy did not change significantly with DMSO or saline treatment.
Reductions in cancer microvascular leakiness induced by a 7-day course of DMSO could be detected and measured by dynamic MMCM-enhanced MRI and were confirmed by microscopic measurements of the leaked macromolecular agents in the same cancers. Results support the robustness of an MMCM-enhanced MRI approach to the characterization of cancers and providing first evidence for an in vivo effect of DMSO on cancer blood vessels.
评估基于动态对比增强磁共振成像(MRI)使用大分子对比剂(MMCM)对血管特征进行定量分析的潜力,以探寻并测量二甲基亚砜(DMSO)对癌症脉管系统的影响,并进行微观相关性分析。
用盐水处理的对照组(n = 8)和用DMSO处理的(n = 7)大鼠人乳腺癌异种移植瘤(MDA-MB-435),在为期1周的3剂量治疗疗程前后,使用白蛋白 - (钆 - 二乙三胺五乙酸)27 - (生物素)11(分子量约90 kDa)通过MMCM增强MRI进行动态成像。治疗后MRI检查后,用凝集素和固定剂灌注肿瘤,随后用RECA-1和链霉亲和素染色进行定量荧光显微镜检查。基于双室动力学模型对癌症微血管通透性(KPS;微升/分钟·100立方厘米)和血浆分数容积(fPV;%)进行MRI定量估计。荧光显微镜检查得出MMCM外渗和血管密度的估计值,并与MRI结果进行比较。
DMSO使癌症血管内皮通透性显著降低(P < 0.05),从肿瘤第0天的KPS = 19.3 ± 8.8微升/分钟·100立方厘米降至第7天的KPS = 0微升/分钟·100立方厘米。盐水处理的肿瘤中的K值无显著变化。通过与MMCM上生物素标签强烈结合的荧光标记链霉亲和素染色测定,DMSO处理的癌症中渗出的白蛋白 - 钆 - (二乙三胺五乙酸)27 - (生物素)11量显著低于对照癌症(P < 0.05)(57.7% ± 5.5%对34.2% ± 4.9%)。MRI测定的fPV以及RECA-1和凝集素染色显微镜检查所反映的肿瘤血管丰富度,在DMSO或盐水处理后无显著变化。
为期7天的DMSO疗程所诱导的癌症微血管渗漏减少,可通过动态MMCM增强MRI检测和测量,并通过对同一癌症中渗漏大分子物质的微观测量得到证实。结果支持MMCM增强MRI方法在癌症特征化方面的稳健性,并为DMSO对癌症血管的体内作用提供了首个证据。